2023-08-04 12:45:15 ET
- Newron Pharmaceuticals press release ( OTC:NWPHF ): 1H GAAP EPS of -€0.39.
- Q2 Licence income/Royalties/Other income of €5.50M vs €2.83M a year ago.
For further details see:
Newron Pharmaceuticals GAAP EPS of -€0.39home / stock / nwphf / nwphf news
2023-08-04 12:45:15 ET
For further details see:
Newron Pharmaceuticals GAAP EPS of -€0.39Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Newron Pharms Spa Ord Company Name:
NWPHF Stock Symbol:
Market:
Ad hoc announcement pursuant to Art. 53 LR Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified Glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients not...
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) for up to one year Presentation of study design for potentially pivotal phase III trial for TRS patients Information on potentially pivotal st...
Ad hoc announcement pursuant to Art. 53 LR EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones Amended agreement envisages EIB will now receive certain performan...